Trial Profile
A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Vorinostat (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions
- 25 Apr 2023 Planned End Date changed from 11 Apr 2023 to 11 Apr 2024.
- 12 Apr 2022 Planned End Date changed from 1 Aug 2012 to 11 Apr 2023.
- 27 Jun 2011 Planned end date changed from 1 Aug 2007 to 1 Aug 2012 as reported by ClinicalTrials.gov.